Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

795 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model.
Carter BZ, Mak PY, Tao W, Ostermann LB, Mak DH, Ke B, Ordentlich P, McGeehan GM, Andreeff M. Carter BZ, et al. Among authors: andreeff m. Haematologica. 2023 Sep 1;108(9):2513-2519. doi: 10.3324/haematol.2022.281927. Haematologica. 2023. PMID: 36727398 Free PMC article. No abstract available.
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. Short NJ, et al. Among authors: andreeff m. J Hematol Oncol. 2023 Jul 8;16(1):73. doi: 10.1186/s13045-023-01476-8. J Hematol Oncol. 2023. PMID: 37422688 Free PMC article. Clinical Trial.
Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
Akiyama H, Kantarjian H, Jabbour E, Issa G, Haddad FG, Short NJ, Hu S, Ishizawa J, Andreeff M, Sasaki K. Akiyama H, et al. Among authors: andreeff m. Int J Hematol. 2024 Aug;120(2):203-211. doi: 10.1007/s12185-024-03787-z. Epub 2024 May 15. Int J Hematol. 2024. PMID: 38748089
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Nguyen D, et al. Among authors: andreeff m. Cancer. 2023 Jun 15;129(12):1856-1865. doi: 10.1002/cncr.34728. Epub 2023 Mar 9. Cancer. 2023. PMID: 36892949 Free article.
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
DiNardo CD, Olin R, Wang ES, Skikne B, Rosenthal J, Kumar P, Sumi H, Hizukuri Y, Hong Y, Patel P, Seki T, Duan T, Lesegretain A, Andreeff M. DiNardo CD, et al. Among authors: andreeff m. Cancer Med. 2024 Jul;13(14):e70028. doi: 10.1002/cam4.70028. Cancer Med. 2024. PMID: 39030997 Free PMC article. Clinical Trial.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Jabbour E, et al. Among authors: andreeff m. Cancer. 2024 Aug 1;130(15):2652-2659. doi: 10.1002/cncr.35317. Epub 2024 Apr 9. Cancer. 2024. PMID: 38591430 Clinical Trial.
795 results